GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » PensionAndRetirementBenefit

MURA (Mural Oncology) PensionAndRetirementBenefit : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology PensionAndRetirementBenefit?

Mural Oncology's PensionAndRetirementBenefit for the quarter that ended in Mar. 2025 was $0.00 Mil.


Mural Oncology PensionAndRetirementBenefit Historical Data

The historical data trend for Mural Oncology's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology PensionAndRetirementBenefit Chart

Mural Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24
PensionAndRetirementBenefit
- - - -

Mural Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mural Oncology PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Mural Oncology Business Description

Traded in Other Exchanges
N/A
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.